Spyre Therapeutics, Inc.
SYRE
Rang in Aktien
#2339
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Aktienkurs
$93.87
Marktkapitalisierung
$8.66B
Veränderung (1 Tag)
2.70%
Veränderung (1 Jahr)
303.74%
Land
US
Handel Spyre Therapeutics, Inc. (SYRE)
Kategorie
Healthcare
Umsatz von Spyre Therapeutics, Inc. (SYRE)
Umsatz im Jun 2026 TTM: $90.49M
Laut den aktuellen Finanzberichten von Spyre Therapeutics, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $90.49M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $886.00K ein Rückgang im Vergleich zu dem Umsatz im Jahr 2022, der $2.33M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Spyre Therapeutics, Inc. von 2014 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $90.49M | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $886.00K | -61.96% |
| 2022 | $2.33M | -87.57% |
| 2021 | $18.74M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $3.89M | -25.30% |
| 2017 | $5.21M | 12.47% |
| 2016 | $4.63M | -23.94% |
| 2015 | $6.09M | 0.00% |
| 2014 | 0.00 | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 13,850.43% |
US
|
|
| $2.23B | 2,362.04% |
US
|
|
| $15.74B | 17,298.20% |
AU
|
|
| $6.02B | 6,553.80% |
NL
|
|
| - | - |
CH
|
